Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NestaCell
- Development stage
- Phase 2
- Lead developer
- Cellavita Scientific Research
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
NestaCell is an allogeneic cell therapy consisting of human dental pulp stem cells (hDPSCs) derived from the exfoliated deciduous teeth of healthy pediatric donors. Developed by Cellavita in collaboration with Instituto Butantan, the therapy is primarily investigated for the treatment of Huntington's disease (HD). The hDPSCs are characterized by high expression of brain-derived neurotrophic factor (BDNF) and Nestin, and low expression of MHC class II molecules, allowing for intravenous administration without the need for immunosuppression. NestaCell is thought to exert therapeutic effects through paracrine mechanisms, providing neurotrophic support and modulating neuroinflammation to mitigate motor and functional decline in neurodegenerative conditions. Clinical trials have demonstrated significant improvements in motor scores and functional capacity in HD patients, supporting its advancement into Phase III development.
- Brand names
- NestaCell
- Other names
- human dental pulp stem cellshDPSCs
Beyond the preview
Go deeper on NestaCell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NestaCell.